Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies

摘要

IntroductionDemographic and disease characteristics may impact response to psoriasis therapies. The objective of this study is to explore the safety and efficacy profile of secukinumab in North American (NA) versus non-NA patients with moderate to severe psoriasis. MethodsData were pooled from four phase?3 studies of secukinumab. Secukinumab (300 and 150?mg) was administered at baseline, weeks?1, 2, and 3, then every 4?weeks from week?4 to 48. ResultsPeak efficacy was observed at week?16 in NA and non-NA patients with secukinumab 300?mg and secukinumab 150?mg, and disease clearance was maintained to week?52. At week?52 with secukinumab 300?mg, Psoriasis Area and Severity Index (PASI) 90/100 response was achieved by 62.9%/37.9% of NA patients, respectively, and 70.2%/42.0% of non-NA patients, respectively. At week?52 with secukinumab 150?mg, PASI?90/100 response was achieved by 30.9%/17.5% of NA patients, respectively, and 53.9%/26.9% of non-NA patients, respectively. Response to secukinumab was rapid, and 50% reduction in mean PASI was achieved in both groups after 2.9?weeks with secukinumab 300?mg and 3.7?weeks with secukinumab 150?mg. ConclusionDespite differences in baseline characteristics, the efficacy and safety of secukinumab were similar among NA and non-NA patients. FundingNovartis Pharma AG. Plain Language SummaryPlain language summary available for this article.